The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for ...

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

will continue to be main therapies for functioning neuroendocrine tumors over the next years. Pasireotide, a new panreceptor analog, might control clinical symptoms and hormone release in patients ...

Laryngeal cancer affects the larynx (voice box) and often can be curable. Here are the treatment and surgical options and how ...

Medically reviewed by Marla Anderson, MD Stomach cancer—or gastric cancer—occurs when cells in the lining of the stomach wall mutate and grow uncontrollably. The stomach wall has five layers, and ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive ...

will continue to be main therapies for functioning neuroendocrine tumors over the next years. Pasireotide, a new panreceptor analog, might control clinical symptoms and hormone release in patients ...